Hikma Pharmaceuticals PLC, commonly known as Hikma, is a leading global pharmaceutical company headquartered in the United Kingdom. Founded in 1978, Hikma has established a strong presence in key operational regions, including the Middle East, North Africa, and the United States. The company operates primarily in the generic and branded pharmaceuticals sectors, focusing on injectable medications, oral solids, and complex generics. Hikma is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that cater to various therapeutic areas, including oncology, pain management, and infectious diseases. With a robust market position, Hikma has achieved significant milestones, including numerous FDA approvals and a growing pipeline of new therapies. The company's dedication to improving patient outcomes and expanding access to essential medicines underscores its reputation as a trusted leader in the pharmaceutical industry.
How does Hikma Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Hikma Pharmaceuticals's score of 67 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Hikma Pharmaceuticals reported total greenhouse gas emissions of approximately 1,000,000,000 kg CO2e, comprising 37,625,000 kg CO2e from Scope 1, 85,682,000 kg CO2e from Scope 2, and a significant 860,710,000 kg CO2e from Scope 3 emissions. This reflects a comprehensive approach to emissions reporting, including all relevant scopes. Hikma has set an ambitious target to reduce its Scope 1 and 2 greenhouse gas emissions by 25% by 2030, using a 2020 baseline. This commitment is part of their broader strategy to achieve net zero emissions by 2050. The company has made progress, reporting a 4% reduction in emissions from direct fuel usage and electricity consumption since 2017. In 2023, the company reported total emissions of approximately 837,000,000 kg CO2e, with Scope 1 emissions at 43,830,000 kg CO2e and Scope 2 emissions at 79,897,000 kg CO2e. The trend indicates a focus on improving sustainability practices and reducing carbon footprints across their operations. Hikma's emissions data is independently reported and does not cascade from any parent organization, ensuring transparency in their climate commitments. The company continues to align its operations with industry standards for climate action, demonstrating a proactive stance in addressing climate change.
Access structured emissions data, company-specific emission factors, and source documents
2013 | 2014 | 2015 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 16,817,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 49,779,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hikma Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.